Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

(2017) Elizabeth Allen et al.   Science Translational Medicine

Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment

(2016) Jin-Sung Park et al.   CANCER CELL

The Basis of Oncoimmunology

(2016) A. Karolina Palucka et al.   CELL

Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity

(2016) Caroline Baer et al.   NATURE CELL BIOLOGY

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

(2016) Sophia Frentzas et al.   NATURE MEDICINE

Ten years of anti-vascular endothelial growth factor therapy

(2016) Napoleone Ferrara et al.   NATURE REVIEWS DRUG DISCOVERY

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

(2016) Jonas Kloepper et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutational landscape ofEGFR-,MYC-, andKras-driven genetically engineered mouse models of lung adenocarcinoma

(2016) David G. McFadden et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer

(2016) Paul E. Hughes et al.   TRENDS IN IMMUNOLOGY

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

(2016) Jeffrey J. Wallin et al.   Nature Communications

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy

(2016) Xinqi Wu et al.   Cancer Immunology Research

Angiopoietin-2: a multifaceted cytokine that functions in both angiogenesis and inflammation

(2015) Alexander Scholz et al.   Annals of the New York Academy of Sciences

The Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy

(2015) Jacques F.A.P. Miller et al.   CANCER CELL

Targeting the tumor vasculature to enhance T cell activity

(2015) Evripidis Lanitis et al.   CURRENT OPINION IN IMMUNOLOGY

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma

(2015) A. Scholz et al.   EMBO Molecular Medicine

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Intertwined regulation of angiogenesis and immunity by myeloid cells

(2015) Lee B. Rivera et al.   TRENDS IN IMMUNOLOGY

Cancer Metastasis: Perivascular Macrophages Under Watch

(2015) E. Kadioglu et al.   Cancer Discovery

Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi Macrophage-Derived VEGFA

(2015) A. S. Harney et al.   Cancer Discovery

Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy

(2015) Lee B. Rivera et al.   Cell Reports

Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma

(2015) X.-D. Liu et al.   Cancer Immunology Research

Changing Treatment Paradigms in Metastatic Breast Cancer

(2015) Cesar A. Santa-Maria et al.   JAMA Oncology

Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia

(2014) Rakesh K. Jain   CANCER CELL

Postsurgical Adjuvant Tumor Therapy by Combining Anti-Angiopoietin-2 and Metronomic Chemotherapy Limits Metastatic Growth

(2014) Kshitij Srivastava et al.   CANCER CELL

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

(2014) Gregory T Motz et al.   NATURE MEDICINE

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

(2014) K. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade

(2014) Nicolò Rigamonti et al.   Cell Reports

Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

(2014) F. S. Hodi et al.   Cancer Immunology Research

Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy

(2013) Y. Huang et al.   CANCER RESEARCH

Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

(2013) Y. Kienast et al.   CLINICAL CANCER RESEARCH

A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors

(2013) Markus Thomas et al.   PLoS One

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects

(2013) John Stagg et al.   Therapeutic Advances in Medical Oncology

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

(2012) Douglas Hanahan et al.   CANCER CELL

Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition

(2012) C. Daly et al.   CANCER RESEARCH

PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-  Inducible Chemokines

(2012) W. Peng et al.   CANCER RESEARCH

G-CSF rescues tumor growth and neo-angiogenesis during liver metastasis under host angiopoietin-2 deficiency

(2012) Jae Hong Im et al.   INTERNATIONAL JOURNAL OF CANCER

Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis

(2012) Tanja Holopainen et al.   JNCI-Journal of the National Cancer Institute

The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities

(2012) Michele De Palma et al.   Molecular Oncology

VEGF-C Promotes Immune Tolerance in B16 Melanomas and Cross-Presentation of Tumor Antigen by Lymph Node Lymphatics

(2012) Amanda W. Lund et al.   Cell Reports

Angiopoietin-2 promotes myeloid cell infiltration in a  2-integrin-dependent manner

(2011) A. Scholz et al.   BLOOD

Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells

(2011) Roberta Mazzieri et al.   CANCER CELL

Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion

(2011) Seth B. Coffelt et al.   JOURNAL OF IMMUNOLOGY

Active Immunotherapy Induces Antibody Responses That Target Tumor Angiogenesis

(2010) J. Schoenfeld et al.   CANCER RESEARCH

Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth

(2010) H. Hashizume et al.   CANCER RESEARCH

Host-Derived Angiopoietin-2 Affects Early Stages of Tumor Development and Vessel Maturation but Is Dispensable for Later Stages of Tumor Growth

(2009) Patrick Nasarre et al.   CANCER RESEARCH

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

(2008) Takuya Osada et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy

(2007) Ronald J Buckanovich et al.   NATURE MEDICINE